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were chosen when closeness of the PTV to the bowel was 
intermediate and doses were 5 x 6.5/9.0/11.0 Gy to 
SIP/main/SIB PTV. 12 fraction regimens were preferred in 
patients with large contact interfaces to bowel OARs and 
doses were 12 x 3.5/4.0/5.0 Gy to SIP/main/SIB PTV. If in 
doubt, a plan for 5 fractions was created and if dose 
constraints were violated a new plan for 12 fractions was 
made. Original dose constraints for OARs for 12 fractions 
were recalculated using EQD2 (equivalent dose in 2 Gy 
fractions) with α/β 3 for late bowel toxicity in an attempt to 
achieve isotoxicity. Proton pump inhibitors (PPI) were 
prescribed prior to SBRT for at least 6 months after 
completion of therapy. 
Results: Since 08/2013 25 patients with the SIB-SIP concept 
were treated with hepatic metastases, primary hepatic 
lesions, Klatskin tumours and pancreatic cancer (PDAC). Most 
often SIP-volumes were small compared to the main PTV and 
14 patients could be treated with 5 fractions, whereas in 11 
patients a 12 fraction regimen was preferred. Acute toxicity 
was < grade 2 in 23 patients. One patient with PDAC had 
grade 3 pain after the 1st of planned 5 fractions which did not 
re-occur after change to the 12-fraction-regimen single 
doses. One patient with PDAC had Forrest grade III gastric 
ulceration after 24/48 Gy (main PTV) despite prophylactic PPI 
intake. None of the patients developed late gastrointestinal 
complications >= grade 2 after a median follow-up of 9 
months and local control rate at 9 months was 81%. 
Conclusions: We here present a novel ICRU-type prescription 
technique for upper abdominal SBRT combining protection of 
bowel OARs with directed boost to the core regions of the 
lesion with favourable initial clinical tolerance and local 
tumour efficacy.  
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Purpose/Objective: The purpose of this study was to analyze 
intra-fractional positioning uncertainty for stereotactic 
radiotherapy and radiosurgery of cranial tumors, including 
primary brain tumors and metastatic disease. Specifically, we 
wish to determine if the use of intra-fractional image guided 
patient positioning verification is necessary during delivery of 
'frameless' stereotactic radiotherapy and radiosurgery 
(SRT/SRS) and non-coplanar radiation beams, and if 
positioning uncertainty is associated with overall treatment 
time.  
Materials and Methods: The patients were treated on an 
accelerator-based stereotactic equipment (NovalisTx with 
micoMLC, Varian/BrainLab). Orthogonal radiographic 
treatment verification data was extracted for 288 
consecutive patients and 1344 fractions, and were analyzed 
with respect to 3D translational and angular corrections once 
during treatment delivery of SRT/SRS (ExacTrac, BrainLab). 
The treatment position was adjusted using 6D corrections 
(Robotics, BrainLab). Association was investigated using 
Spearman signed rank test and p-values less than 0.05 were 
considered significant.  
Results: The study shows that positioning corrections greater 
than 2 mm are required for ca. 6% of the beams (see Fig.1). 
Further, the magnitude of the translational corrections and 
the maximum angular deviations were both significantly 
associated with the delay time between the beams (p<0.006) 
(see Table 1). In addition, the maximum angular and 
translational deviations were associated (p<0.001).  
Table 1. Spearman correlation coefficients for the treatment 
beams investigated.  
 
Parameter Association Rho 
Significance  
(2-tailed) 
Lateral dev. Long. dev. -0.007 0.785 
Vertical dev. Long. dev. -0.039 0.157 
Lateral dev. Vertical dev. -0.012 0.672 
Max angular dev. Delay time 0.092 0.006 
3D deviation Delay time 0.376 0.000 
3D deviation 
Max angular 
dev. 
0.174 0.000 
 
Conclusions: We conclude that a subgroup of SRT/SRS 
patients may have considerable positioning error unless this is 
monitored and corrected during treatment, and that keeping 
the imaging and delivery times short is beneficial towards 
clinically relevant geographical misses.  
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Purpose/Objective: To identify the main pitfalls and 
challenges and their possible sources in clinical target volume 
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(CTV) delineation for postoperative gastric cancer (GC). The 
effect of a dedicated training course on interobserver 
variability in the CTV delineation among residents in 
radiation oncology was evaluated. 
Materials and Methods: Twenty residents from several 
institutions delineated the CTV for the same case of 
postoperative GC before and after a training course on target 
volume definition. CTV was delineated on four planning 
computed tomography (CT) scans: the dome of the 
diaphragm, the anterior abdominal wall, the duodenal stump 
and the porta hepatis level. Participants were also asked to 
determine the most caudal scan of the CTV. The rough 
volume of the CTV for each participant was reconstructed 
from all requested planar contours. The reference contours 
were proposed by the senior radiation oncologist. Area of 
Intersection (AI) and Volume of Intersection (VI), defined as 
the overlap of delineated area/volume with respective 
reference area (RA)/ reference volume (RV), were computed 
using dedicated software for each participant. AI was 
calculated for each requested CT scan. The degree of 
agreement between the reference contours and participants’ 
delineations was quantified using the Concordance Index (CI) 
for respective areas and volumes, defined as the percent 
ratio of the AI or VI to the RA or RV (AI/RA•100% or 
VI/RV•100%). Additional analysis of the lower CTV border 
(distance from the reference level) was performed. The CIs 
for areas and volumes obtained before and after the course 
were compared using the Student t-test. A questionnaire was 
developed to gather data regarding the difficulties the 
participants faced during the CTV delineation before and 
after the course. 
Results: The mean value of CI for all participants was the 
lowest for the dome of the diaphragm and for the duodenal 
stump (24% and 49% before the course, 35% and 61% after the 
course, respectively). The highest mean CI was recorded for 
the abdominal wall (73% before and 83% after the course). 
For all delineated CT scans, CI was higher after than before 
the course, although the differences were not statistically 
significant. Mean CI for the CTV volume was 49% before and 
59% after the course, respectively, p = 0.17. The mean 
distance from the reference to the participants' lower CTV 
borders was 2.73 cm before and 2.0 cm after the course, 
respectively, p = 0.17. In a questionnaire, 75% of respondent 
indicated the elective nodal area as the main difficulty when 
contouring the CTV, particularly with regard to para-aortic, 
mesenteric and porta hepatis lymph nodes. 
Conclusions: Elective nodal area is the main subjective 
difficulty faced in CTV delineation for postoperative GC, 
however the largest interobserver variability was shown for 
the dome of the diaphragm. The differences tended to 
decrease after the course.  
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Purpose/Objective: Conventional dark ink tattoos used for 
external references during breast radiotherapy can negatively 
impact patients' long term cosmetic outcomes, serve as a 
reminder of their diagnosis and treatment and be incorrectly 
identified in patients with dark skin tone. Fluorescent tattoos 
offer an innovative solution to overcome these limitations 
but have not previously been clinically tested. This study 
evaluates the efficacy of using fluorescent tattoos together 
with the impact on patient experience in those undergoing 
breast radiotherapy. The primary endpoint was inter-fraction 
reproducibility (population random error) determined using 
electronic portal imaging (EPI). 
Materials and Methods: Prior to recruitment, extensive pilot 
work was performed to assess visibility of fluorescent inks 
with a selection of UV torches. Forty six patients receiving 
adjuvant radiotherapy for BC were randomised to receive 
either fluorescent (n=24) or conventional dark-ink tattoos 
(n=22). Tattoos were administered bilaterally and midline. 
EPI data was used to determine setup accuracy and compared 
between groups using a one sided t-test. Timing data was 
recorded at CT planning and treatment sessions to identify 
resource requirements. A validated body image scale (BIS) 
was completed at baseline (pre-treatment), 1 month and 6 
months post planning scan to determine the impact of tattoo 
type on body image. 
Results: Pilot work demonstrated that optimum torch and 
fluorescent ink selection was paramount for safe and 
effective application of this method. No adverse effects were 
reported and fluorescent tattoos were visible in 22 of 24 
patients. Fluorescent tattoos could not be sufficiently 
visualised in two patients with sub-Saharan skin tone and 
they were re-tattooed with conventional dark ink. Random 
displacements for the fluorescent tattoo group were less than 
2.8mm in the anterior-posterior and cranio-caudal directions 
(p= 0.001; p=0.009 respectively). There were no statistically 
significant differences in random and systematic errors 
between the two groups. There was a modest increase in 
setup time (mean=1.4mins) associated with fluorescent 
tattoos. BIS scores were worse at 1 month in 50% of patients 
with dark ink tattoos compared to only 24% of patients with 
fluorescent tattoos (six month results available 2015).  
Conclusions: The use of external reference fluorescent 
tattoos with optimum UV torches is an innovative alternative 
to using conventional dark ink for breast radiotherapy. EPI 
data suggests there is no significant difference in inter-
fraction reproducibility. Analysis of body image data suggests 
that, for a proportion of breast radiotherapy patients, use of 
fluorescent tattoos can improve patient experience and 
enhance survivorship. 
  
 
